cAMP is a potent inhibitor of cell proliferation in a variety of cell lines. Downregulation of cyclin D1 and upregulation of the cell cycle inhibitor p27 Kip1 are two mechanisms by which cAMP may induce a G1-arrest. Here we show that cAMP inhibits proliferation of cells that constitutively express cyclin D1 or are deficient for Rb, demonstrating that changes in these cell cycle regulators do not account for the cAMP-induced growth effects in mouse embryo fibroblasts (MEFs). Interestingly, the antiproliferative effect of cAMP mimics the effect previously observed for FoxO transcription factors. These transcription factors are under negative control of protein kinase B (PKB). We show that in MEFs cAMP strongly induces transcriptional activation of FoxO4 through the inhibition of PKB. Accordingly, not only p27
Introduction
cAMP is an important regulator of proliferation, through modulation of cAMP-dependent protein kinase A (PKA). Depending on the cell type, cAMP can either stimulate or inhibit proliferation. Inhibition of proliferation by cAMP takes place in the G1-phase of the cell cycle, and involves the cyclin-dependent kinase (CDK) complexes cyclin D1-CDK4/6 and cyclin E/A-CDK2 as well as the CDK inhibitors (CKIs) p21
Cip1 and p27
Kip1
. Indeed, inhibition of cell proliferation by cAMP has most often been reported to correlate with and partially depend on a decrease in cyclin D1 or an increase in p27
Kip1 (Sewing et al., 1993; Kato et al., 1994; Vadiveloo et al., 1997; Williamson et al., 1997; Kim et al., 2001b; van Oirschot et al., 2001) . The main pathways involved in the regulation of p27 Kip1 and cyclin D1 are the MAPK and PI3K pathways (Lavoie et al., 1996; Aktas et al., 1997; Muise-Helmericks et al., 1998; Medema et al., 2000) . Inhibition of the MAPK pathway by cAMP is well documented and takes place at the level of Raf kinase (Burgering et al., 1993; Cook and McCormick, 1993) , which is phosphorylated by PKA (Wu et al., 1993; Hafner et al., 1994; Mischak et al., 1996; Dumaz et al., 2002) . Inhibition of the MAPK pathway alone, however, cannot account for the G1-arrest induced by cAMP (McKenzie and Pouyssegur, 1996; Dumaz et al., 2002; Balmanno et al., 2003) . Also, the PI3K pathway may be inhibited by cAMP, but this has only been shown in a restricted number of cell types and the mechanism is elusive. It has been suggested that cAMP inhibits the pathway at the level of PI3K itself, resulting in disturbed PIP3 formation and PDK1 membrane localization (Kim et al., 2001a; Lee and Kay, 2003) .
Cyclin D1 in complex with CDK4 or CDK6 promotes proliferation by inhibiting the retinoblastoma (Rb) protein, which on its turn blocks E2F transcription factors and thus the induction of genes involved in DNA replication (Sherr and Roberts, 1999) . MAPK regulates cyclin D1 levels transcriptionally, via the ATF/CREB family of transcription factors and the CREB response element (CRE) in the cyclin D1 promoter (Lee et al., 1999) . The PI3K/PKB pathway regulates cyclin D1 levels transcriptionally via regulation of FoxO transcription factors (Ramaswamy et al., 2002; Schmidt et al., 2002) , at the translational level involving p70S6 kinase (Muise-Helmericks et al., 1998; Takuwa et al., 1999) , and post-transcriptionally by targeting it for degradation using GSK3b (Diehl et al., 1998) .
The cell cycle inhibitor p27 Kip1 acts during late G1-phase by binding and inhibiting CDK2-cyclin E/A complexes (Sherr and Roberts, 1999) . Cells can only progress through the cell cycle when p27
Kip1 is dissociated from the CDK2-cyclin E/A complexes, and this is in general achieved by degradation of p27
Kip1 (Pagano et al., 1995; Malek et al., 2001) . Degradation of p27
Kip1 is usually initiated through phosphorylation by CDK2 (Muller et al., 1997; Vlach et al., 1997) , but may also involve calpains (Delmas et al., 2003) , caspases (Loubat et al., 1999) or jab1 (Tomoda et al., 1999) . Furthermore, p27
Kip1 protein can be regulated at the transcriptional level by FoxO transcription factors (Medema et al., 2000) or by translational regulation (Agrawal et al., 1996; Hengst and Reed, 1996) . Finally, p27
Kip1 activity can also be diminished by sequestering it in cyclin D-CDK complexes (Sherr and Roberts, 1999) or by nuclear exclusion, which is preceded by phosphorylation of p27
Kip1 by protein kinase B (PKB) or KIS (Boehm et al., 2002; Fujita et al., 2002; Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002) .
The picture that emerges is one in which cAMP affects different cell cycle components by multiple mechanisms. This, together with cell-type differences has obstructed identification of a uniform mechanism of cAMP-induced cell cycle arrest. For example, it has been hypothesized that the combined downregulation of cyclin D1 and upregulation of p27
Kip1 would be sufficient (L'Allemain et al., 1997), but actual proof for this is lacking. Interestingly, upregulation of p27 Kip1 and downregulation of cyclin D1 is part of the program by which FoxO transcription factors induce a G1 arrest in nonhematopoietic cells (Medema et al., 2000; Ramaswamy et al., 2002; Schmidt et al., 2002) . These FoxO transcription factors are negatively regulated by the PI3K/PKB pathway, and direct phosphorylation of FoxOs by PKB leads to nuclear exclusion (Brunet et al., 1999; Brownawell et al., 2001) . Therefore, we have tested here the involvement of FoxO in a cAMP-induced growth arrest. We show that in mouse embryo fibroblasts (MEFs) apart from the MAPK pathway, the PKB/FoxO pathway plays a prominent role in the antiproliferative effect of cAMP.
Results

Inhibition of the MAPK pathway and cyclin D1 by cAMP is not sufficient for the induction of a G1-arrest in cycling MEFs
We choose to study the growth inhibitory effects of cAMP in MEFs based on the fact that these cells are known to be responsive to cAMP and the existence of MEFs, derived from mice in which various cell cycle regulators have been deleted by targeted gene disruption. First, we compared the effects of the cAMPelevating compound forskolin (in combination with the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX)) and that of the MEK-inhibitor U0126 on wild-type MEFs grown in the presence of serum. Whereas both compounds inhibited the ERK pathway equally well (Figure 1a ), forskolin/IBMX was clearly more effective in inhibiting proliferation (Figure 1b left panel). We then investigated the level of cyclin D1 under both conditions and found that cyclin D1 was clearly downregulated by forskolin/IBMX, but only weakly and transiently downregulated by U0126 (Figure 1c upper panel). To see if this difference in cyclin D1 expression could explain the difference in growth rate, we made use of cycD1 MEFs, in which cyclin D1 is expressed under the control of a constitutive promoter at levels comparable to those seen in proliferating cells (Schmidt et al., 2002) . As expected, forskolin/IBMX did not change cyclin D1 expression in these cells (Figure 1c lower panel). Despite this, the inhibition of growth by forskolin/IBMX was only slightly less as compared to that of wild-type cells. Furthermore, forskolin/IBMX was still more potent in inhibiting proliferation than U0126 (Figure 1b right panel and Table 1 ). These findings are consistent with other data showing a partial involvement of the MAPK pathway and/or cyclin D1 in a cAMP-induced cell cycle arrest (McKenzie and Pouyssegur, 1996; Dumaz et al., 2002; Balmanno et al., 2003) . Subsequently, we tested the role of Rb, which acts downstream of cyclin D1, in the antiproliferative effect of cAMP. However, proliferation of Rb-deficient 3T3 cells was still inhibited by forskolin/IBMX, to a comparable level as seen in cycD1 MEFs ( Figure 2a and Table 1 ). Interference of apoptosis in the measurement of proliferation could be excluded, as there was no significant increase in apoptotic cells (Figure 2b , sub-G1 fraction). Furthermore, forskolin/IBMX clearly induced a G1-arrest in the Rb À/À cells, comparable to wild-type cells ( Figure 2b and Supplementary Figure) , whereas U0126 led to a minor increase. Changes seen in cyclin D1 levels after forskolin/IBMX treatment were identical to those seen in wild-type MEFs (Figure 2c ). We conclude that promoting the inhibitory action of Rb on E2F is not the only mechanism for a cAMP-induced G1 arrest in MEFs. This is in agreement with our observation that constitutively expressing cyclin D1 hardly affects the antiproliferative effect of cAMP.
p27
Kip1 plays an important role in inhibition of proliferation by cAMP To see if in addition to MAPK, p27 Kip1 is involved in cAMP-induced G1-arrest of MEFs, we first measured the protein levels of this cell cycle inhibitor. A clear increase in p27
Kip1 levels up to at least 48 h after stimulation with forskolin/IBMX was seen, whereas U0126 gave a weaker and more transient increase ( Figure 3a) . Furthermore, stimulation with forskolin/ IBMX induced translocation of p27
Kip1 to the nucleus (Figure 3b ), where it is known to exert its inhibitory action. In contrast, hardly any p27
Kip1 translocated after stimulation with U0126 (data not shown). To investigate the importance of p27
Kip1 for inhibition of proliferation by cAMP, we made use of p27 Kip1 -deficient MEFs. Although these cells grow slower than wild-type cells, proliferation of the p27 À/À MEFs was significantly less inhibited by treatment with forskolin/IBMX as compared to wild-type cells. Furthermore, the residual inhibition of proliferation by cAMP was almost comparable to the effect of U0126 on proliferation ( Figure 3c and Table 1 ). In addition, cell cycle analysis showed that the increase in p27
Kip1
-deficient cells in G1 À/À cells were stimulated with U0126 and forskolin/IBMX for the indicated time points. Cyclin D1 protein levels and GAPDH as a control were visualized by immunoblotting was only 5%, which is clearly lower than the 15% increase seen in wild-type cells (Supplementary Figure) . Together, this demonstrates that upregulation of p27 Kip1 in MEFs contributes to cAMP-induced growth arrest but is not solely responsible for this effect.
cAMP regulates p27
Kip1 levels via transcriptional activity of FoxO transcription factors
To test if cyclin D1 in the absence of p27
Kip1 upregulation would overcome a cAMP-induced G1-arrest, we tried to generate p27
Kip1 knockout MEFs, constitutively expressing cyclin D1. However, whereas we could express cyclin D1 in wild-type MEFs, p27
Kip1 knockout MEFs expressing cyclin D1 appeared unstable. We then reasoned that FoxO transcription factors have been shown to inhibit proliferation by regulating both cyclin D1 and p27
Kip1 levels (Medema et al., 2000; Ramaswamy et al., 2002; Schmidt et al., 2002) . To investigate whether these transcription factors play a role in a cAMPinduced arrest, the effect of forskolin/IBMX on FoxO activity was tested. A reporter construct containing six DAF-16 family protein-binding elements (DBEs), which is known to be activated by FoxO family members (Furuyama et al., 2000) , was used for this purpose. Luciferase activity was increased by co-transfection of FoxO4 and clearly elevated upon stimulation with cAMP ( Figure 4a) . cAMP was not able to increase luciferase activity in the absence of co-transfected FoxO4 or in the presence of an active FoxO4 mutant, which is mutated at its PKB phosphorylation sites (FoxO4-A3) (Figure 4a and data not shown), indicating that cAMP indeed regulates 6xDBE activity via FoxO transcription factors. The next step was to investigate whether regulation of the p27
Kip1 promoter by cAMP was FoxO-dependent. To this end, a reporter construct containing the p27
Kip1 promoter (À1609 to þ 178) (Kwon et al., 1996) was used. Treatment of cells with forskolin/IBMX elevated FoxO4-induced luciferase activity, whereas in the absence of co-transfected FoxO4, cAMP was not able to stimulate the p27 Kip1 promoter (Figure 4b) . Moreover, reporter gene activity induced by active FoxO4 was not enhanced by forskolin/IBMX treatment (Figure 5d ). Furthermore, we investigated whether protein levels of p27
Kip1 are increased by cAMP via FoxOs. We transiently transfected MEFs with active PKB (gagPKB), the DNA binding domain of FoxO4 (FoxO4-DB), which acts as dominant-negative FoxO, or active FoxO4, and examined the effect of cAMP on the total levels of p27 Kip1 . Whereas active FoxO4 in the absence of cAMP increased p27 Kip1 levels, the basal level of p27 Kip1 was lower in the presence of active PKB or dominantnegative FoxO4. Furthermore, the increase of p27 Kip1 levels caused by cAMP was clearly reduced by overexpression of active PKB and to a lesser extent by dominant-negative FoxO4. No complete inhibition of the cAMP-induced p27 Kip1 levels was seen, which may be explained by the fact that not all cells were transfected or by additional inputs on the p27 Kip1 promoter. Active FoxO4 could, as reported before, induce p27
Kip1 protein levels, but interestingly, forskolin/IBMX did not increase this (Figure 4c) . Together, these data show that cAMP can regulate FoxO transcriptional activity and that PKB and FoxO mediate cAMP-induced expression of p27 Kip1 . If cAMP is able to regulate FoxO transcription factors, FoxO targets other than p27
Kip1 are predicted to be regulated as well. We were particularly interested in the FoxO target manganese superoxide dismutase (MnSOD), as we previously showed that MnSOD by scavenging reactive oxygen species (ROS) plays a role in protecting cells from going into apoptosis . Thus, MnSOD might protect cAMP-arrested cells, which are not apoptotic (data not shown). Indeed, MnSOD protein levels were increased in MEFs after stimulation with forskolin/IBMX for 24 or 48 h, whereas U0126 did not have an effect (Figure 4d ). Kip1 . Cells were stimulated as indicated and fixed to slides. p27 Kip1 protein was stained by immunofluorescence and nuclei were stained with DAPI. (c) Inhibition of proliferation of p27-deficient cells is partially reversed by cAMP. p27 À/À MEFs were subjected to a proliferation assay as in Figure 1a . The average proliferation, calculated from three independent experiments, is shown, with error bars representing s.d. The presence of p27 Kip1 protein was checked on a Western blot with GAPDH as a control
cAMP-induced G1-arrest involves inhibition of PKB, leading to enhanced activity of FoxO transcriptional factors
We next addressed the question as to how cAMP regulates FoxO transcription factors. Given that the PI3K/PKB pathway directly affects FoxO activity (Kops et al., 1999) , we measured PKB phosphorylation as a read-out for PI3K activity. Due to the fact that we grew the cells in the continuous presence of serum, PKB activity is elevated as compared to that in serum-starved cells, with insulin treatment giving only a mild further increase. Phosphorylation of both serine 473 and threonine 308 of PKB was rapidly decreased upon stimulation with forskolin/IBMX and this inhibition was sustained (Figure 5a and b) , thus correlating with p27 Kip1 upregulation. In contrast, U0126 led to a reduced activity of PKB only at later time points. Furthermore, inhibition of the PI3K pathway using the inhibitor LY294002 resulted in an increase in G1 in Rb-deficient cells, almost comparable to the effect of forskolin/ IBMX (data not shown). Thus, cAMP-mediated growth arrest might be largely dependent on activation of FoxOs due to inhibition of PI3K/PKB by cAMP. To confirm that the observed decrease in PKB phosphorylation affected phosphorylation of PKB sites in FoxO members, total cell lysates were probed with a phosphospecific antibody against threonine 32 of FoxO3a. Indeed, phosphorylation of this PKB site was strongly diminished by forskolin/IBMX treatment up to at least 48 h (Figure 5c ). To further corroborate this, we tested the effect of constitutively active PKB (gagPKB) on cAMP-induced, FoxO-mediated activation of the p27 Kip1 promoter. Both activation of the p27 Kip1 -promoter by FoxO4 and the increased activity due to forskolin/ IBMX treatment were completely inhibited by cotransfection of active PKB. As expected, forskolin/ IBMX treatment did not increase the transcriptional activity of FoxO4-A3, which cannot be phosphorylated by PKB (Figure 5d ). Together, these experiments show that cAMP mediates activation of FoxO transcription factors via inhibition of PKB, which results in enhanced transcription from the p27 Kip1 -promoter. To prove that FoxO transcription factors are indeed important in a cAMP-induced cell cycle arrest, the DNA binding domain of FoxO4 (FoxO4-DB) was overexpressed in MEFs. This protein is expected to act as a dominant negative for all FoxO family members. We assessed the inhibition of proliferation by determining the increase in the G1-phase of the cell cycle by cAMP. A clear, albeit incomplete, reversion of cAMP-induced inhibition of proliferation was seen both at 24 and 48 h Kip1 -promoter activity in a FoxO-dependent manner. The experiment was performed as in (a), except that the p27 Kip1 -promoter luciferase construct was used. (c) cAMP regulates p27
Kip1 protein levels partially via PKB and FoxOs. MEFs were transfected either with empty vector, gagPKB, HA-tagged FoxO4-A3 or HA-tagged FoxO4-DB, and cells were stimulated for 24 h with forskolin/IBMX or were left untreated. Proteins were separated and blotted and membranes were probed for total p27
Kip1 levels. Membranes were probed for PKB or HA to visualize the transfected proteins. As a control for equal loading, the blot was probed for GAPDH. (d) cAMP upregulates MnSOD protein levels. MEFs were stimulated with forskolin/IBMX or with U0126 for 8, 24 or 48 h or the cells were serum starved (SS) for 28 h. MnSOD levels were visualized by immunoblotting and GAPDH was used as a control by overexpression of FoxO4-DB (Figure 5e ). Together these data demonstrate a clear involvement of FoxO transcription factors in cAMP-induced cell cycle arrest.
Discussion
The mechanism of inhibition of proliferation by cAMP is a complex process, analysis of which is further complicated by cell-type-dependent differences. Consistent with previous reports, we show here that inhibition of the MAPK pathway and cyclin D1 levels cannot fully account for the cAMP-induced cell cycle arrest in MEFs, and that p27
Kip1 upregulation is clearly important as well. This is evident from the finding that cAMPinduced inhibition of proliferation is partly reversed in p27 Kip1 -deficient cells. Apparently, the antiproliferative effect of cAMP in MEFs cannot be explained by upregulation of p27 Kip1 alone. In other cell types, the most likely partner in the process of inhibition of proliferation is cyclin D1. For example, in hamster fibroblasts (L'Allemain et al., 1997) and T cells (van Oirschot et al., 2001) , overexpression of cyclin D at least partially overcomes the antiproliferative effect of cAMP. However, constitutive expression of cyclin D1 in MEFs has hardly any effect on cAMP-induced growth arrest. Moreover, Rb-deficient cells are also clearly inhibited in proliferation by cAMP, indicating that changes in cyclin D1 and Rb activity are not sufficient to explain the cAMP effect. It could be argued that in the Rb-deficient cells, proliferation is still inhibited due to redundancy between Rb family members. We could exclude this, as MEFs deficient for all three Rb family members, Rb, p130 and p170 (Dannenberg et al., 2000) , are still arrested upon cAMP treatment, which is only partly due to the induction of apoptosis (HBK, unpublished observation).
Here we report that FoxO transcription factors, which are under the negative control of the PI3K/PKB Figure 5 PKB and FoxOs are involved in cAMP-induced cell cycle arrest. (a) cAMP inhibits PKB-phosphorylation for long term in MEFs. MEFs were stimulated for 6, 24 or 48 h with forskolin/ IBMX (F/I) or U0126, or 6 h with insulin (ins), or were left untreated. Equal protein amounts were blotted and blots were probed for both phosphorylated PKB at serine 473 and at threonine 308 and as a control blots were probed for GAPDH. (b) PKB phosphorylation is inhibited at early time points. MEFs were treated for the indicated time points with forskolin/IBMX. PKB, phosphorylated at serine 473, and total PKB levels as a control were visualized by immunoblotting. (c) Phosphorylation of FoxO by PKB is inhibited by cAMP. Cells were stimulated for 6, 24 or 48 h with forskolin/IBMX, U0126 or were left untreated. FoxO3a, phosphorylated at threonine 32, total FoxO3a and total PKB protein levels were visualized by immunoblotting. (d) PKB is involved in cAMP-dependent regulation of the p27 Kip1 promoter. The experiment was performed as in Figure 4b , using the p27 Kip1 luciferase construct. In addition, cells were co-transfected with active PKB (gagPKB) or transfected with an active FoxO4 mutant (FoxO4-A3). Error bars represent s.d. (e) FoxOs are involved in cAMP-induced cell cycle arrest. MEFs were transfected with either an empty vector (EV) or HA-tagged FoxO4-DB (DB). In two independent experiments, the cells were treated with forskolin/ IBMX for either 24 or 48 h. The cell cycle profile was determined as in Figure 2b . The percentage increase in G1-phase cells of forskolin/IBMX stimulated cells compared to unstimulated cells was calculated and plotted for each experiment separately. Furthermore, the fold increase in G1 of DB-transfected cells versus EV-transfected cells is shown in numbers. Part of the cells used for FACS analysis was lysed before fixation to check for the presence of transfected constructs. Lysates were separated and blotted, and blots were stained for HA to visualize HA-FoxO4-DB and total PKB levels were visualized as a control pathway, are involved in the antiproliferative effect of cAMP in MEFs. First, FoxO transcription factors can downregulate cyclin D1 and upregulate p27
Kip1 (this report and Medema et al., 2000; Nakamura et al., 2000; Ramaswamy et al., 2002) . Furthermore, at least one other direct target of FoxO transcription factors, namely MnSOD, is upregulated following cAMP treatment. Regulation of FoxO transcription factors by cAMP is clearly observed in co-transfection experiments in which transcription from a 6xDBE luciferase construct was increased by forskolin/IBMX. In contrast, an active version of FoxO4, FoxO4-A3, did not respond to cAMP. More direct evidence for a role of FoxO transcription factors in the antiproliferative effect of cAMP comes from ectopic expression of dominantnegative FoxO4. FoxO4-DB clearly interferes in growth inhibition by cAMP, although this effect is not complete. This may be due to the fact that not all cells were transfected or that FoxO4-DB cannot fully block the action of endogenous FoxO transcription factors. An equally likely possibility however is that not all growth inhibitory effects of cAMP are mediated via activation of FoxOs. In line with this is the observation that ectopic expression of cyclin D1 does partially protect cells from a FoxO4-induced cell cycle arrest (Schmidt et al., 2002) , whereas ectopic expression of cyclin D1 does hardly affect a cAMP-induced cell cycle arrest (Table 1) . The most likely way by which cAMP activates FoxOs is via inhibition of PI3K. Although we did not directly measure decreases in PIP3 levels, the PI3K-regulated PKB was clearly less phosphorylated at S473 and T308. Moreover, phosphorylation of FoxO3a at threonine 32, which is one of the PKB-sites, was strongly decreased by cAMP treatment. Furthermore, induction of the p27 Kip1 -promoter and p27
Kip1 protein levels by cAMP could both clearly be suppressed by active PKB.
Besides its antiproliferative effect, cAMP is known to protect certain cell types from apoptosis (Parvathenani et al., 1998; Li et al., 2000; Boucher et al., 2001) . We now show that this might also be the case in mouse fibroblasts via a mechanism using MnSOD. MnSOD is a known target of FoxOs and is clearly upregulated by cAMP, which is thus a likely consequence of stimulation of FoxOs on FoxO binding sites in the MnSOD promoter. MnSOD upregulation might provide the cells with a mechanism in which cells can be protected when PKB is inhibited.
Apart from cyclin D1 or Rb, p21 Cip1 might be involved next to p27
Kip1 in a cAMP-induced cell cycle arrest. Although we were not able to show an increase in p21 Cip1 levels upon cAMP treatment in wild-type MEFs (data not shown), this has been shown by others in other cell types (Rao et al., 1999; Lee et al., 2000) . Furthermore, it has been shown that FoxO transcription factors can cooperate with TGFb to induce p21
Cip1 levels transcriptionally (Seoane et al., 2004) . Recently, we obtained preliminary evidence that FoxO transcription factors can regulate p21 Cip1 levels in the absence of TGFb treatment as well (BMTB, unpublished observation). It would therefore be interesting to see if cAMP can still inhibit proliferation of p21/p27 double knockout cells.
Materials and methods
Cell culture, plasmids, antibodies and reagents
Culturing of Rb-deficient 3T3 cells, MEFs constitutively expressing cyclin D1, p27 Kip1 -deficient MEFs and wild-type MEFs has been described before (Medema et al., 2000; Schmidt et al., 2002) . All cells used were cultured in DMEM, supplemented with 10% fetal bovine serum and 0.05% glutamine.
pMT2-HA-FoxO4, -DB, -A3, pSG5-gagPKB, pGL3-6xDBE-luc and pGL2-p27 Kip1 -1609-luc have been described (Burgering and Coffer, 1995; Kwon et al., 1996; Kops et al., 1999; Furuyama et al., 2000; Medema et al., 2000) .
Antibodies directed against the following proteins were used: phospho-Thr202/Tyr204-p44/42 MAPK, phospho-Ser473 and -Thr308-PKB (Cell Signaling), phospho-Thr32-FKHRL1 (Upstate) and FKHRL1 (sc-11351; Santa Cruz) for detection of FoxO3a, PKB (Burgering and Coffer, 1995) , cyclin D1 (Immunotech), GAPDH (Chemicon), HA (12CA5; (Burgering and Coffer, 1995) ), ERK2 (de Vries-Smits et al., 1992), p27 (Transduction Laboratories) and MnSOD (Stressgen).
The following stimuli and inhibitors were used at the following concentrations: forskolin (10 mM; ICN), IBMX (0.5 mM; Sigma), insulin (1 mg/ml; Sigma), U0126 (10 mM; Biomol Research Laboratories) and LY294002 (10 mM; Sigma).
Transfections and immunoblotting
Cells were transfected, using the calcium phosphate precipitation method, aPEI (Durocher et al., 2002) or using the transfection agent fugene (Roche). In the case of pBabe-puro co-transfections, the cells were selected for at least 24 h with 1 mg/ml puromycin. Following stimulation, cells were lysed by scraping in Ripa lysis buffer (20 mM Tris-HCl pH 7.5, 1% triton X-100, 0.5% Na-DOC, 0.1% SDS, 10 mM EDTA, 150 mM NaCl), supplemented with aprotinin, leupeptin, trypsin inhibitor, Na 3 VO 4 and NaF. Ripa lysates were cleared by centrifugation and protein amounts were equalized, using standard Bradford protein quantification methods. Proteins were separated on SDS-polyacrylamide gels and blotted onto polyvinylidene difluoride membranes (NENt), following incubations with primary and secondary antibodies. Proteins were visualized using standard enhanced chemiluminescence and autoradiography.
Proliferation assay
Cells were plated in multiwell plates in triplicates, following stimulation the next day. Medium and stimuli were refreshed every 2 days and the cells were stained at 3 different days, 0-6 days after stimulation. To stain, the cells were fixed for 10 min in 10% acetic acid at RT, prior to 10 min staining at RT with 0.4% crystal violet, dissolved in 10% acetic acid. The plates were washed twice with water and dried overnight. Proliferation was quantified by measuring the optical density at wavelength 560 nm of the in 10% acetic acid re-dissolved crystal violet stain in the plates.
Flow cytometry
For determination of cell cycle distributions, untransfected cells or cells transfected with the indicated constructs together with pBabe-puro were used. Cells were stimulated for 24 or 48 h as indicated and transfected cells were selected with 1 mg/ml puromycin for at least 24 h. Cells were detached using EDTA, containing trypsin, and washed twice. Nonadherent cells, like apoptotic cells, were collected by centrifugation of the tissue culture medium and pooled with the detached cells. Subsequently, cells were fixated in 70% ethanol for at least 16 h at 41C. Hereafter, cells were washed and resuspended in PBS, containing 0.1% BSA, 0.25 mg/ml RNase and propidium iodide and were incubated for 30 min at 371C prior to DNA profile measurements. Flow cytometry analysis was performed using a FACScalibur instrument (Becton Dickinson).
Luciferase assay
Cells were transfected in triplicates with renilla-luc and either 6xDBE-luc or p27 Kip1 -promoter-luc, together with either pMT2-HA empty vector or pMT2-HA-FoxO4 and cells were stimulated as indicated. At 2 days after transfection, cells were lysed in passive lysis buffer (Promega) for 30 min at RT, where after lysates were cleared. Luciferase counts were measured using the dual-luciferase reporter assay system (Promega).
Immune fluorescence
Cells were plated on cover slides and stimulated for the indicated time points, followed by fixation in 4% paraformaldehyde solution in PBS. Cells were blocked with blocking buffer (0.1% saponin and 0.5% BSA in PBS), followed by incubation with an anti-p27
Kip1 antibody. Subsequently, the cells were incubated with a donkey-anti-mouse-Cy3 conjugated antibody and DAPI. Cells were visualized using a Zeiss fluorescence microscope.
